OnCo

Pembrolizumab monotherapy

Checked 2026-09-09

Adjuvant melanoma stage IIB-IV (1 year); PD-L1 TPS 50% or above NSCLC; MSI-high tumours; recurrent head and neck (CPS 1 or above)

One cycle

every 21 days
178141521Pembrolizumab: 200 mg every 3 weeks or 400 mg every 6 weeks, IntravenousPembrolizumab
21-day cycle, up to 35 cycles (2 years); 17 cycles adjuvant melanomaIntravenous

Components

DrugDoseRouteDays
Pembrolizumab
Monoclonal antibody (anti-PD-1)
200 mg every 3 weeks or 400 mg every 6 weeksIVD1
Cycles
up to 35 cycles (2 years); 17 cycles adjuvant melanoma
21-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine

Used in

Source

KEYNOTE-006, NEJM 2015; FDA label (flat dosing)

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers